Cell and gene therapies are disrupting medicine at every level! For patients this could mean a long awaited treatment or even cure. However, bringing such a therapy to market is a journey unlike any other, with rapidly changing expectations, and many other hidden hurdles.
We’re reshaping the health economic landscape to work for cell and gene therapies. Join us on that journey and we’ll showcase the true value of your product
’Once and done’, curative therapies have an intrinsically different value to other medicines. This changes both the way that value needs to be presented, and the data required to measure and convey it
Expectations are high, and hope is palpable; patients want your therapy to succeed. Managing all of this and delivering on their (and your) aspirations, requires a new kind of relationship
The very concept of your therapy is revolutionary and could be at odds with the clinical status quo. Preparing the clinical community for this disruption requires a sea-change in your strategy, planning and tactics
Whether you are moving from clinical development to commercialisation, or have an avid IR following to manage, every decision, every hire, every communication matters more than ever before
Built with expertise from across MEDiSTRAVA, GenEra can help you navigate the journeys ahead by providing a wealth of practical assistance to guide you through approval, maximise access and drive adoption. Ultimately we help ensure patients receive and benefit from your innovative therapies.
Working with us ensures you can leverage our in-depth knowledge and unique experience, providing you with added confidence on your journey to a successful and rewarding launch.
Let us work together to remove the hurdles from your journey.
